The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Eli Lilly is requesting medical records from patients who took compounded versions of tirzepatide amid safety concerns and ...

Months earlier, the agency released a report alleging the companies drove up the costs of some medications, including insulin ...

The three price benefit managers jointly administer 80% of all prescriptions in the U.S., the FTC said in the lawsuit.

(Reuters) - The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing ...

The Federal Trade Commission sued the drug middlemen that health plans use to keep a lid on drug spending, accusing the firms ...

The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.81% and ...